Background/Aims: Previous reports highlighted the potential interest of cetuximab alone or in combination with chemotherapy in locally advanced or metastatic cutaneous squamous cell carcinomas (cSCC) care. Material and Methods: To further evaluate the efficiency and safety of cetuximab in advanced cSCC, a single-center retrospective study including all patients treated with cetuximab alone or combined with carboplatin for locally advanced or metastatic cSCC was conducted in a tertiary referral center. The primary end point was the overall response rate (ORR) after 2 cycles of treatment. Secondary end points were best overall disease control rate (DCR), overall survival (OS), best response duration, progression-free survival (PFS), and toxicity profile. Results: Of the 14 enrolled patients, no complete response was obtained after 2 cycles of treatment, but 3 partial responses and 6 stable diseases were observed. ORR and DCR were 21.4 and 64.3%, respectively. Median OS and PFS were 9.25 and 2.65 months, respectively. Median PFS was longer with combined treatment compared with cetuximab monotherapy (9.03 vs. 3.55 months). The safety profile was acceptable with a trend toward a relationship between acne-like rash and longer response (median PFS 5.2 vs. 2.2 months). Discussion/Conclusion: In all series including ours, disease control is usually rapidly obtained with cetuximab alone or combined with conventional chemotherapy, although with a minority of partial responses and no complete response. However, this control is of short duration in most cases. The safety profile is acceptable. A randomized phase III trial is warranted to better assess the benefit/risk ratio.

1.
Karia PS, Han J, Schmults CD: Cutaneous squamous cell carcinoma: estimated incidence of disease, nodal metastasis, and deaths from disease in the United States, 2012. J Am Acad Dermatol 2013;68:957-966.
2.
Rogers HW, Weinstock MA, Feldman SR, Coldiron BM: Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the US population, 2012. JAMA Dermatol 2015;151:1081-1086.
3.
Maubec E, Duvillard P, Velasco V, Crickx B, Avril M-F: Immunohistochemical analysis of EGFR and HER-2 in patients with metastatic squamous cell carcinoma of the skin. Anticancer Res 2005;25:1205-1210.
4.
Burtness B, Goldwasser MA, Flood W, et al: Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 2005;23:8646-8654.
5.
Vermorken JB, Trigo J, et al: Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007;25:2171-2177.
6.
Frampton JE: Spotlight on cetuximab in squamous cell carcinoma of the head and neck. Bio Drugs 2011;25:129-133.
7.
Cohen MH, Chen H, Shord S, Fuchs C, He K, Zhao H, Sickafuse S, Keegan P, Pazdur R: Approval summary: cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil for the first-line treatment of patients with recurrent locoregional or metastatic squamous cell head and neck cancer. Oncologist 2013;18:460-466.
8.
Bauman JE, Eaton KD, Martins RG: Treatment of recurrent squamous cell carcinoma of the skin with cetuximab. Arch Dermatol 2007;143:889-892.
9.
Suen JK, Bressler L, Shord SS, Warso M, Villano JL: Cutaneous squamous cell carcinoma responding serially to single-agent cetuximab. Anticancer Drugs 2007;18:827-829.
10.
Arnold AW, Bruckner-Tuderman L, Zuger C, Itin PH: Cetuximab therapy of metastasizing cutaneous squamous cell carcinoma in a patient with severe recessive dystrophic epidermolysis bullosa. Dermatology 2009;219:80-83.
11.
Rubió Casadevall J, Graña-Suárez B, Hernandez-Yagüe X, Vayreda Ribera J, Huc Grasa O, Brunet Vidal J: Xeroderma pigmentosum: neck lymph node metastasis of a squamous cell carcinoma of the skin treated with cetuximab. Eur J Dermatol 2009;19:163-165.
12.
Miller K, Sherman W, Ratner D: Complete clinical response to cetuximab in a patient with metastatic cutaneous squamous cell carcinoma. Dermatol Surg 2010;36:2069-2074.
13.
Kamaria M, Shea CR, Chin RK, Cohen EE, Maggiore R, Bolotin D: Eruptive cutaneous squamous cell carcinoma and psoriasis response to cetuximab. Clin Exp Dermatol 2014;39:604-607.
14.
Suen JK, Bressler L, Shord SS, Warso M, Villano JL: Cutaneous squamous cell carcinoma responding serially to single-agent cetuximab. Anticancer Drugs 2007;18:827-829.
15.
Jalili A1, Pinc A, Pieczkowski F, Karlhofer FM, Stingl G, Wagner SN: Combination of an EGFR blocker and a COX-2 inhibitor for the treatment of advanced cutaneous squamous cell carcinoma. J Dtsch Dermatol Ges 2008;6:1066-1069.
16.
Göppner D, Nekwasil S, Franke I, Gollnick H, Leverkus M: Successful combination therapy of a locally advanced squamous cell carcinoma of the skin with cetuximab and γ-irradiation. J Dtsch Dermatol Ges 2010;8:826-828.
17.
Giacchero D, Barrière J, Benezery K, Guillot B, Dutriaux C, Mortier L, et al: Efficacy of cetuximab for unresectable or advanced cutaneous squamous cell carcinoma - a report of eight cases. Clin Oncol 2011;23:716-718.
18.
Wollina U, Schreiber A, Merla K, Haroske G: Combined cetuximab and volumetric modulated arc-radiotherapy in advanced recurrent squamous cell carcinoma of the scalp. Dermatol Reports 2011;3:e57.
19.
Kalapurakal SJ, Malone J, Robbins KT, Buescher L, Godwin J, Rao K: Cetuximab in refractory skin cancer treatment. J Cancer 2012;3:257-261.
20.
Mecca C1, Ponzetti A, Caliendo V, Ciuffreda L, Lista P: Complete response of metastatic cutaneous squamous cell carcinoma to cetuximab plus paclitaxel. Eur J Dermatol 2012;22:758-761.
21.
Alter M1, Satzger I, Mattern A, Kapp A, Gutzmer R: Treatment of advanced cutaneous squamous cell carcinomas with epidermal growth factor receptor inhibitors. Dermatology 2013;227:289-294.
22.
Eder J1, Simonitsch-Klupp I, Trautinger F: Treatment of unresectable squamous cell carcinoma of the skin with epidermal growth factor receptor antibodies - a case series. Eur J Dermatol 2013;23:658-662.
23.
Kim M, Li M, Intong LR, Tran K, Melbourne W, Marucci D, Bucci J, de Souza P, Mallesara G, Murrell DF: Use of cetuximab as an adjuvant agent to radiotherapy and surgery in recessive dystrophic epidermolysis bullosa with squamous cell carcinoma. Br J Dermatol 2013;169:208-210.
24.
Conen KL, Fischer N, Hofbauer GF, Shafaeddin-Schreve B, Winterhalder R, Rochlitz C, Zippelius A: Cetuximab in metastatic squamous cell cancer of the skin: a Swiss case series. Dermatology 2014;229:97-101.
25.
Falivene S, Giugliano FM, Grimaldi AM, Di Franco R, Toledo D, Muto M, Cammarota F, Borzillo V, Ascierto PA, Muto P: Tomotherapy concomitant with cetuximab, followed by cetuximab as single-agent therapy for unresectable squamous cell carcinoma of the skin: a case report. BMC Dermatol 2014;14:15.
26.
Samstein RM, Ho AL, Lee NY, Barker CA: Locally advanced and unresectable cutaneous squamous cell carcinoma: outcomes of concurrent cetuximab and radiotherapy. J Skin Cancer 2014;90:761-768.
27.
Maubec E, Petrow P, Scheer-Senyarich I, Duvillard P, Lacroix L, Gelly J, et al: Phase II study of cetuximab as first line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol 2011;29:3419-3426.
28.
Preneau S, Rio E, Brocard A, Peuvrel L, Nguyen JM, Quéreux G, Dreno B: Efficacy of cetuximab in the treatment of squamous cell carcinoma. J Dermatolog Treat 2014;25:424-427.
29.
Reigneau M, Robert C, Routier E, Mamelle G, Moya-Plana A, Tomasic G, Mateus C: Efficacy of neoadjuvant cetuximab alone or with platinum salt for the treatment of unresectable advanced nonmetastatic cutaneous squamous cell carcinomas. Br J Dermatol 2015;173:527-534.
30.
Hecht JR, Mitchell E, Neubauer MA, et al: Lack of correlation between epidermal growth factor receptor status and response to panitumumab monotherapy in metastatic colorectal cancer. Clin Cancer Res 2010;16:2205-2213.
31.
Tol J, Dijkstra JR, Klomp M, et al: Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab. Eur J Cancer 2010;46:1997-2009.
32.
Carthon BC, Ng CS, Pettaway CA, Pagliaro LC: Epidermal growth factor receptor-targeted therapy in locally advanced or metastatic squamous cell carcinoma of the penis. BJU Int 2014;113:871-877.
33.
Lynch MC, Drabick JJ, Neves RI, Fox EJ, Mackley HB, Anderson BE: Palliative effect of capecitabine and cetuximab for refractory metastatic squamous cell carcinoma of the perineum in epidermodysplasia verruciformis. Skinmed 2014;12:54-56.
34.
Rescigno P, Matano E, Raimondo L, Mainolfi C, Federico P, Buonerba C, Di Trolio R, D'Aniello C, Damiano V, Palmieri G, De Placido S, Di Lorenzo G: Combination of docetaxel and cetuximab for penile cancer: a case report and literature review. Anticancer Drugs 2012;23:573-577.
35.
Posch D, Fuchs H, Kornek G, Grah A, Pammer J, Aretin MB, Fuereder T: Docetaxel plus cetuximab biweekly is an active regimen for the first-line treatment of patients with recurrent/metastatic head and neck cancer. Sci Rep 2016;6:32946.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.